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Abstract
Dyslipidemia is a major risk factor for development of several obesity-related diseases. The peroxisome proliferator-
activated receptor a (PPARa) is a ligand-activated transcription factor that regulates energy metabolism. Previously, we
reported that 9-oxo-10,12-octadecadienoic acid (9-oxo-ODA) is presented in fresh tomato fruits and acts as a PPARa agonist.
In addition to 9-oxo-ODA, we developed that 13-oxo-9,11-octadecadienoic acid (13-oxo-ODA), which is an isomer of 9-oxo-
ODA, is present only in tomato juice. In this study, we explored the possibility that 13-oxo-ODA acts as a PPARa agonist in
vitro and whether its effect ameliorates dyslipidemia and hepatic steatosis in vivo. In vitro luciferase assay experiments
revealed that 13-oxo-ODA significantly induced PPARa activation; moreover, the luciferase activity of 13-oxo-ODA was
stronger than that of 9-oxo-ODA and conjugated linoleic acid (CLA), which is a precursor of 13-oxo-ODA and is well-known
as a potent PPARa activator. In addition to in vitro experiment, treatment with 13-oxo-ODA decreased the levels of plasma
and hepatic triglycerides in obese KK-Ay mice fed a high-fat diet. In conclusion, our findings indicate that 13-oxo-ODA act as
a potent PPARa agonist, suggesting a possibility to improve obesity-induced dyslipidemia and hepatic steatosis.
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Introduction
Obesity is a major risk factor for chronic diseases including
diabetes, cardiovascular diseases, and hypertension [1–4]. Dysli-
pidemia, in particular, is a direct risk factor for arteriosclerosis, and
for liver cirrhosis, and may be partially due to the dysfunction of
lipid metabolism in the liver. Therefore, to prevent or reduce
arteriosclerosis and cirrhosis, it is important to ameliorate the
dysfunction of hepatic lipid metabolism dysfunction.
Peroxisome proliferator-activated receptors (PPARs) are ligand-
activated transcription factors and members of the nuclear
hormone receptor superfamily, which regulate energy homeostasis
(glucose and lipid metabolisms), inflammation, proliferation, and
differentiation [5–9]. In particular, PPARa acts as a master
regulator of fatty acid oxidation by controlling the transcription of
its target genes [10,11]. Consistent with this function, PPARa is
mainly expressed in tissues with high lipid catabolic capacities,
such as the liver, skeletal muscle, and brown adipose tissue [7,12].
It has been reported that the activation of PPARa enhances fatty
acid oxidation in the liver and decreases the levels of circulating
and cellular lipids in obese diabetic patients [9,13]. Therefore, the
regulation of PPARa activity is one of the most important means
of managing chronic disease related to dysfunction in lipid
metabolism in the liver.
During the past decade, numerous studies have shown that
endogenous and naturally occurring biological molecules, includ-
ing fatty acids and fatty acid-derivatives, serve as PPARa agonists
[14,15]. In particular, conjugated linoleic acid (CLA) is well known
as a potent PPARa agonist [16] and treatment with CLA actually
increases the catabolism of lipids in the liver in rodents [17].
However, the effects of CLA derivatives on PPARa remain
unclear.
Recently, we reported that a particular CLA derivative, 9-oxo-
10,12-octadecadienoic acid (9-oxo-ODA), is present in fresh
tomato fruit, and serves as a PPARa agonist [18]. In mouse
primary hepatocytes, 9-oxo-ODA enhanced fatty acid oxidation
via PPARa activation and consequently inhibited triglyceride
accumulation [18]. Interestingly, we developed that processed
products such as tomato juice contain 13-oxo-9,11-octadecadenoic
acid (13-oxo-ODA), an isomer of 9-oxo-ODA, which was not
present in fresh tomato fruit [19].
In this study, we explored whether 13-oxo-ODA acts as a
PPARa agonist in vitro and ameliorates dyslipidemia and hepatic
steatosis in vivo. Treatment with 13-oxo-ODA activated PPARa in
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mouse primary hepatocytes. Furthermore, treatment of obese
diabetic KK-Ay mice with 13-oxo-ODA suppressed the increase
in plasma and hepatic triglyceride (TG) levels resulting from a
high-fat diet (HFD), through PPARa activation in peripheral
tissues such as the liver and skeletal muscle. In addition, 13-oxo-
ODA treatment decreased the plasma glucose level and increased
glucose the tolerance ability in the 13-oxo-ODA-fed mice, as has
been shown for other PPARa agonists. These findings indicate
that 13-oxo-ODA has a possibility to improve the disorder of lipid
and carbohydrate metabolism, via PPARa activation.
Materials and Methods
Plant materials and chemicals
The compound 13-oxo-9,11-ODA was synthesized by Shinsei
Chemical Company, Ltd. (Osaka, Japan), and 9,11-octadecadienic
acid (conjugated linoleic acid; CLA) was purchased from Cayman
Chemical (MI, U.S.A). All other chemicals were purchased from
Sigma (MO, U.S.A), Wako (Osaka, Japan), or Nacalai Tesque
(Kyoto, Japan), and were guaranteed to be of reagent grade or
tissue-culture grade.
Luciferase assay
Luciferase assays were performed as previously described, using
a GAL4/PPAR chimera system [20,21]. We transfected
p4xUASg-tk-luc (a reporter plasmid), pM-hPPARa (an expression
plasmid for a chimera protein for the GAL4 DNA-binding domain
and each human PPAR-ligand-binding domain), and pRL-CMV
(an internal control for normalizing transfection efficiency) into
monkey CV1 kidney cells by using Lipofectamine (Invitrogen
Corp.), according to manufacturer’s protocol. Luciferase activity
was assayed using the dual luciferase system (Promega, MO,
U.S.A) according to the manufacturer’s protocol.
Preparation of mouse primary hepatocytes
Mouse hepatocytes were prepared as previously described [18].
Briefly, C57/BL/6J male mice were anesthetized with intraper-
itoneal administration of Nembutal and the liver was perfused with
liver perfusion medium (Invitrogen Corp.), followed by liver
digestion medium (Invitrogen Corp.). Hepatocytes were dispersed
in hepatocyte wash medium (Invitrogen Corp.) by dissection and
gentle shaking. After filtration through a 100-mm nylon mesh filter,
hepatocytes were isolated by repeated centrifugation at 50 g for
3 min (3 times). The isolated hepatocytes were cultured in type-1
collagen-coated 12-well plates (Iwaki, Chiba, Japan). After 5-h
incubation at 37uC in 5% CO2 atmosphere, the hepatocytes were
used for mRNA quantification assay.
Animal experiments
Male KK-Ay mice, a useful model of obesity and diabetes [22],
were purchased from CLEA Japan (Tokyo, Japan). The mice were
kept in individual cages in a temperature-controlled room at
2461uC and maintained under a constant 12-h light/dark cycle.
All animal experiments were approved by Kyoto University
Animal Care Committee (approval ID: No. 22–53).
To determine the effects of 13-oxo-ODA on the development of
diabetic conditions, we used 4-week-old mice. The mice were
maintained for 5 days on a standard diet and then divided into 3
groups of similar average body weight. Each group was
maintained on 60% HFD (D12492; Research Diets, NJ, USA)
or on HFD containing 0.02% (w/w) or 0.05% 13-oxo-ODA for 4
weeks. The energy intake of all the mice was adjusted by pair
feeding. The energy intake of all the mice was adjusted by pair
feeding. Thus, the levels of food intake of each group was similar
(average food intakes were 3.4260.05, 3.3060.09, and
3.5360.02 g/day in the groups fed control HFD, 0.02% 13-
oxo-ODA, and 0.05% 13-oxo-ODA, respectively).
An oral glucose tolerance test (OGTT) was performed on the
KK-Ay mice fed the experimental diet for 3 weeks [23]. For
OGTT, glucose (1.5 g/kg body weight) was administered orally
after overnight fasting, and blood samples collected from the tail
vein before and 15, 30, 60, 90, and 120 min after the
administration.
During the 4 weeks of the treatment period, the rectal
temperature of all the mice was also measured using a
thermometer probe (T&D Corp., Nagano, Japan).
At the end of the treatment period, anesthetized mice were
killed by cervical dislocation after overnight fasting, and blood
samples were collected. Plasma TG and glucose levels were
determined by the TG E-test and glucose CII-test (Wako),
respectively. Plasma insulin and adiponectin concentrations were
measured using an ultrasensitive mouse insulin kit (Morinaga
Institute of Biological Science, Yokohama, Japan) and ELISA kits
(BD Bioscience, CA, USA), respectively. All kits were used in
accordance with the manufacturer’s protocols.
Histological analysis of liver
Liver samples were removed from each animal and fixed in
10% formaldehyde/PBS. The fixed samples were embedded in a
tissue-freezing medium (Tissue-Tek OCT compound; IN, USA)
and frozen in acetone cooled with liquid nitrogen. Cryostat
sections of 10-mm thickness were prepared at 220uC, fixed in 50%
ethanol/water for 5 min, and then stained with Oil Red O. The
sections were counterstained with Mayer’s hematoxylin.
Measurements of TG contents in tissues
To determine liver and skeletal muscle TG contents, TGs were
extracted from those tissues with chloroform/methanol by the
Bligh Dyer method [24]. TG concentration was measured using
the TG E-test (Wako).
Quantification of mRNA expression levels
Total RNA was prepared from primary hepatocytes, as well as
liver and skeletal muscle, using Sepasol (Nacalai Tesque),
according to the manufacturer’s protocols. Using M-MLV reverse
transcriptase (Invitrogen, Corp.), total RNA was reverse-tran-
scribed using a thermal cycler (Takara PCR Thermal Cycler SP:
Takara Bio Inc., Shiga, Japan). To determine mRNA expression
levels, real-time quantitative RT-PCR analysis was performed
with a Light Cycler System (Roche Diagnostics) using SYBR green
fluorescence signals, as described previously [20,25].
The oligonucleotide primer sets of mouse 36B4, PPARa target
genes, and TG synthesis related genes were designed using a PCR
primer selection program at the website of the Virtual Genomic
Center from the GenBank database as follows: mouse CPT1a
(Fwd: 59-ctcagtgggagcgactcttca-39; Rev: 59-ggcctctgtggtacacgacaa-
39), mouse CPT1b (Fwd: 59-ctgttaggcctcaacaccgaac-39; Rev: 59-
ctgtcatggctaggcggtacat-39), mouse AOX (Fwd: 59-gcaccattgccattc-
gataca-39; Rev: 59-acggctattctcacagcagtgg-39), mouse FAT/CD36
(Fwd: 59-gatgtggaacccataactggattcac-39; Rev: 59-ggtcccagtctcatt-
tagccacagt-39), mouse ACS (Fwd: 59- acatccacgtgtatgagttctacgc-39;
Rev: 59-agtagacgaagttctcacggtcgat-39), mouse UCP2 (Fwd: 59-
cactttccctctggataccgc-39; Rev: 59-gatcccttcctctcgtgcaat-39). mouse
SREBP1c (Fwd: 59-ggagccatggattgcacatt-39; Rev: 59-gccagagaag-
cagaagagaag-39), mouse ABCA1 (Fwd: 59-ggacttggtaggacggaacct-
39; Rev: 59-tcctcatcctcgtcattcaaa-39), mouse ABCG1 (Fwd: 59-
aagacctgcactgcgacatc-39; Rev: 59-tggtcacaatctctgctttg-39), mouse
FAS (Fwd: 59-tgggttctagccagcagagt-39; Rev: 59-accaccagagaccgt-
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tatgc-39), and mouse 36B4 as an internal control (Fwd: 59-
tgtgtgtctgcagatcgggtac-39; Rev: 59-ctttggcgggatttagtcgaag-39). All
data indicating mRNA expression levels are presented as a ratio
relative to a control in each experiment.
Immunoblotting assay
Immunoblotting was carried out as previously described [18].
The anti-mouse AOX antibody was obtained from Abcam Corp.
(MA, U.S.A). Anti-mouse b-actin and horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG was purchased from Santa
Cruz Biotechnology Inc. (CA, U.S.A). Protein bands were detected
by chemiluminescence using an enhanced chemiluminescence
system (NEN Lifescience Products) in accordance with the
manufacturer’s instructions.
Statistical analyses
Data are presented as mean6 SEM. The data were assessed for
statistical significance by 1-way ANOVA and Dunnet’s multiple
comparison tests. Differences were considered significant when p
was ,0.05.
Results
13-oxo-ODA serves as PPARa ligand
First, we investigated whether 13-oxo-ODA (Fig. 1A) activated
PPARa in a luciferase ligand assay by using the GAL4/PPAR
chimera system and CV1 cells, and found that treatment with 13-
oxo-ODA increased luciferase activity in a dose-dependent
manner as well as that of GW7647, a synthetic PPARa agonist
(Fig. 1B). Furthermore, we compared the PPARa reporter
activities in response to 13-oxo-ODA vs. 9-oxo-ODA (Fig. 1A),
which is an isomer of 13-oxo-ODA [19] and acts as a PPARa
activator [18]. Interestingly, the luciferase activity generated by
13-oxo-ODA was stronger than that of 9-oxo-ODA (Fig. 1B).
Moreover, the luciferase activity of 13-oxo-ODA also showed
higher than that of CLA, which is a precursor of 13-oxo-ODA
[26] and is a well-known PPARa agonist (Fig. 1).
To elucidate whether 13-oxo-ODA induces PPARa activation
in intact cells, we examined the effects of 13-oxo-ODA on mRNA
expression levels of PPARa target genes in mouse primary
hepatocytes. As expected, treatment with 13-oxo-ODA for 24 h
significantly increased the mRNA expression levels of carnitine-
palmitoyl transferase 1a (CPT1a; subtype of liver), acyl-CoA
oxidase (AOX), fatty acid translocase (FAT), acyl-CoA synthase
(ACS), and uncoupling protein 2 (UCP2) in the primary
hepatocytes similar to the treatment with CLA (Fig. S1).
Furthermore, to investigate whether these effects of 13-oxo-ODA
depend on PPARa, we coadministered 13-oxo-ODA and
GW6471, a PPARa-specific antagonist [27]. The increase in
those mRNA expression levels by 13-oxo-ODA was abolished by
GW6471, although the basal levels of these mRNA expressions
remained unchanged. These findings indicate that 13-oxo-ODA, a
CLA-derivative, activates PPARa in hepatocytes.
13-oxo-ODAtreatment improved dyslipidemia and
lowering TG content in the liver and skeletal muscle of
HFD-fed KK-Ay mice
To determine in vivo effects of 13-oxo-ODA on the develop-
ment of obesity-related metabolic dysfunction, KK-Ay mice were
fed a HFD containing 0.02% or 0.05% synthesized 13-oxo-ODA
for 4 weeks. The body weights showed no significant differences
between the control HFD-fed and 13-oxo-ODA-fed groups (The
average body weights were 36.260.51, 36.360.75, and
37.160.58, in the groups fed control HFD, 0.02% 13-oxo-
ODA, and 0.05% 13-oxo-ODA, respectively). In addition of body
weights, the weights of white adipose tissues, liver, skeletal
muscle, and brown adipose tissue showed no significant
differences between the control HFD-fed and 13-oxo-ODA-fed
groups (data not shown). However, plasma TG concentration
significantly decreased in the 0.05% 13-oxo-ODA-fed mice
(Fig. 2A), as did TG content in the liver and skeletal muscle
(Fig. 2B and C). Furthermore, Oil red O staining of the liver
sections supported this finding, by showing that TG accumulation
was suppressed in the liver of the 13-oxo-ODA-treated mice
(Fig. 2D) but was present at high levels in the liver of the control
mice. The suppression was more apparent in the 0.05% 13-oxo-
ODA-containing HFD-fed mice than in the 0.02% 13-oxo-ODA-
containing HFD-fed mice, suggesting a dose effect. Thus these
findings indicate that treatment with 13-oxo-ODA suppresses the
obesity-induced TG accumulation in the liver and skeletal
muscle.
Figure 1. Effects of 13-oxo-ODA on PPARa activation deter-
mined by luciferase assay and using mouse primary hepato-
cytes. (A) Chemical structures of 13-oxo-ODA, 9-oxo-ODA, and CLA. (B)
A reporter plasmid (p4xUASg-tk-luc) and an expression vector for a
GAL4 PPARa chimeric protein (pM-hPPARa) were transfected into CV1
cells together with an internal control reporter plasmid (pRL-CMV).
Twenty-four hours after the transfection, the cells were treated with
synthesized CLA or 13-oxo-ODA for 24 h. GW7647 (5 nM), which is a
PPARa-specific agonist, was used as a positive control. Luciferase
activity was measured using a dual luciferase system. The activity of a
vehicle control was set at 100%, and the relative luciferase activities are
presented as fold induction with respect to that of the vehicle control.
Data are presented as mean6 SEM (n= 425). **; p,0.01 versus control.
#; p,0.05 compared between indicated groups.
doi:10.1371/journal.pone.0031317.g001
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13-oxo-ODA treatment induced expression of PPARa
target genes in the liver and skeletal muscle
To determine the mechanism by which 13-oxo-ODA decreased
plasma and hepatic TG concentrations, we measured mRNA
expression levels of genes involved in fatty acid metabolism in the
liver. The mRNA expression levels of CPT1a, AOX, FAT, ACS, and
UCP2 were increased in the liver by the 0.05% 13-oxo-ODA
treatment (Fig. 3A). In contrast, treatment with 13-oxo-ODA
didn’t affect mRNA expression levels of genes involved in TG
synthesis such as sterol regulatory element-binding protein 1c
(SREBP1c), ATP-binding cassette sub-family A member 1 (ABCA1),
ABCG1, and fatty acid synthase (FAS) (Fig. 3B). Additionally, the
expression level of the AOX protein was increased by treatment
with 13-oxo-ODA (Fig. 3C). Furthermore, we measured the effect
of 13-oxo-ODA on these mRNA expression levels in the skeletal
muscle, in which PPARa is highly expressed same as the liver. 13-
oxo-ODA treatment induced mRNA expressions of CPT1b
(subtype of skeletal muscle), AOX, FAT, ACS, and UCP2 in the
skeletal muscle (Fig. 4A), whereas mRNA expressions of SREBP1c,
ABCA1, ABCG1, and FAS didn’t change by 13-oxo-ODA
treatment (Fig. 4B). Thus these findings indicate that treatment
with 13-oxo-ODA induced the mRNA expression levels of genes
involved in fatty acid metabolism, but did not affect TG synthesis-
related genes expression in the liver and skeletal muscle.
13-oxo-ODA treatment increased the rectal temperature
A previous study showed that rectal temperature increases
concomitantly with energy expenditure, and that PPARa
activation increases rectal temperature [28]; therefore we
measured rectal temperature of the mice. In this study, the rectal
temperature was 0.67uC higher in the 0.05% 13-oxo-ODA-treated
mice than in the control mice (Fig. 5). Together, these findings
indicate that 13-oxo-ODA increases the mRNA expression levels
of PPARa target genes in the liver and skeletal muscle, thereby
increasing fatty acid oxidation in these tissues.
13-oxo-ODA improved carbohydrate metabolism in HFD-
fed KK-Ay mice
Finally, to investigate the effects of 13-oxo-ODA on carbohy-
drate metabolism in vivo, we examined plasma levels of glucose in
the 13-oxo-ODA-treated mice. As shown in Figs. 6A and B, 4-
week HFD feeding resulted in high plasma levels of glucose and
insulin, suggesting that the mice showed indications of diabetes.
However, 13-oxo-ODA treatment significantly decreased both
plasma glucose and insulin concentrations (22% and 32%
decreases in the 0.02% and 0.05% 13-oxo-ODA-fed mice,
respectively). In addition, the concentration of plasma adiponectin,
an adipocytokine that improves insulin resistance [29], increased
in the 13-oxo-ODA-fed mice (Fig. 6C). Furthermore OGTT
showed that the plasma glucose concentration in the 0.05% 13-
oxo-ODA-fed mice decreased more rapidly than that in the
control mice (Fig. 7).
Discussion
PPARa is activated by endogenous agonists, which include fatty
acids and their derivatives such as eicosanoids and oxidized fatty
acids, as well as by synthetic compounds [6,30–32]. In this study,
we explored whether the oxidized fatty acid, 13-oxo-ODA, which
is an isomer of 9-oxo-ODA that is present in tomato, acts as a
PPARa agonist [18]. Luciferase reporter assays revealed that 13-
oxo-ODA induced PPARa activation in a dose-dependent
manner. Furthermore, 13-oxo-ODA increased mRNA expression
levels of PPARa target genes in mouse primary hepatocytes. These
Figure 2. Effects of 13-oxo-ODA on plasma and hepatic TG contents in HFD-fed KK-Ay mice. Plasma TG concentration (A) and hepatic TG
content (B) at the end of treatment period. Data are presented as mean6 SEM (n= 425). *; p,0.05 versus control. (C) Isolated livers were fixed in 10%
formalin/PBS for more than 24 h and then embedded. Liver sections were cut into 10 mm sections. The liver sections were stained with Oil Red O and
Mayer’s hematoxylin. A bar shown in each photograph indicates 50 mm.
doi:10.1371/journal.pone.0031317.g002
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activities of 13-oxo-ODA were similar to those of 9-oxo-ODA
(data not shown). In addition, the activities of 13-oxo-ODA were
similar to those of CLA, which is considered a functional nutrient
Figure 3. Effects of 13-oxo-ODA on mRNA expression levels of
genes involved in lipid metabolism in the liver of HFD-fed KK-
Ay mice. The mRNA expression levels of genes involved in fatty acid
metabolism (CPT1a, AOX, FAT, ACS, and UCP2; Fig. 3A) and in TG synthesis
(SREBP1c, ABCA1, ABCG1, and FAS; Fig. 3B) in the liver of control and 13-
oxo-ODA-fed mice were quantified by real-time PCR. The relative amount
of each transcript was normalized to the amount of the 36B4 transcript.
The expression levels in the vehicle control are set at 100% and the
relative expression levels are presented as fold induction with respect to
that in the vehicle control. (C) Protein expression of AOX and b-actin in
the liver of control and 13-oxo-ODA-fed mice were compared by
immunoblotting assay. The same amounts of protein (25 mg/lane) were
loaded and blotted onto PVDF membranes. The membranes were
sequentially treated with primary antibodies as indicated and secondary
antibodies conjugated with HRP. The enhanced chemiluminescence
system was used for visualization of membranes. Data are presented as
mean 6 SEM (n= 628). *; p,0.05 versus control.
doi:10.1371/journal.pone.0031317.g003
Figure 4. Effects of 13-oxo-ODA on mRNA expression levels of
genes involved in lipid metabolism in the skeletal muscle of
HFD-fed KK-Ay mice. The mRNA expression levels of genes involved
in fatty acid metabolism (CPT1b, AOX, FAT, ACS, and UCP2; Fig. 4A) and
in TG synthesis (SREBP1c, ABCA1, ABCG1, and FAS; Fig. 4B) in the skeletal
muscle of control and 13-oxo-ODA-fed mice were quantified as
described before. Data are presented as mean 6 SEM (n = 628).
*; p,0.05, **; p,0.01 versus control.
doi:10.1371/journal.pone.0031317.g004
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that improves abnormalities of lipid metabolism by activating
PPARa [16] and increasing fatty acid oxidation [33]. Thus, our
findings suggest that 13-oxo-ODA, as a PPARa agonist, is also
valuable for control of lipid metabolism, similar to 9-oxo-ODA
and CLA.
It has previously been established that activation of PPARa
enhances fatty acid oxidation in the liver and decreases the levels
of circulating and hepatic lipids in obese diabetic mice [9,13].
When we examined the in vivo effects of 13-oxo-ODA in obese
KK-Ay mice fed a HFD for 4 weeks, we found that treatment with
13-oxo-ODA increased the mRNA expression levels of PPARa
target genes such as CPT1, AOX, CD36, ACS, and UCP2 in both
the liver and skeletal muscle. Furthermore, the rectal temperature,
which indicates energy metabolism [28], was significantly higher
in the 13-oxo-ODA-treated mice than in the control mice.
Moreover, 13-oxo-ODA treatment suppressed increases plasma
and hepatic TG in the obese KK-Ay mice fed HFD. However, 13-
oxo-ODA didn’t affect to the weights of body and WAT in this
experiment. We think this period of treatment with 13-oxo-ODA
(4weeks) may be too short to decrease the weights of body and
WAT. Therefore, we need a longer treatment with 13-oxo-ODA
for examining effects on weights of body and WAT, in addition to
the decreases in hepatic and plasma levels of TG. These findings
indicate that 13-oxo-ODA serves as a PPARa agonist both in vivo
and in vitro, and suggested a possibility that 13-oxo-ODA is a
beneficial food-derived compound for controlling plasma and
hepatic levels of TG under obese and diabetic conditions.
It has also previously been shown that PPARa plays an
important role in carbohydrate metabolism in addition to lipid
metabolism [34], by enhancing fatty acid clearance from insulin-
sensitive tissues, such as the liver and skeletal muscle [35]. Indeed,
in this study, the treatment with 13-oxo-ODA also decreased the
levels of plasma glucose and insulin. Furthermore, it has recently
been revealed that PPARa agonists directly and transcriptionally
increase adiponectin production via adipose PPARa activation
[36,37]. It has been well-known that adiponectin improves insulin
resistance [38]. In fact, the plasma adiponectin level in 13-oxo-
ODA-treated mice significantly increased. Thus the increase in
plasma adiponectin level induced by the 13-oxo-ODA treatment
may contribute to the improvement of insulin resistance.
A number of previous studies have shown that tomato products,
especially tomato juices, contain various beneficial natural
Figure 6. Effects of 13-oxo-ODA on carbohydrate metabolism
in HFD-fed KK-Ay mice. Fasting plasma glucose (A), insulin (B), and
adiponectin (C) in the KK-Ay mice fed HFD with or without 13-oxo-ODA
for 4 weeks. Each bar represents the mean 6 SEM (n= 628). *; p,0.05
versus control.
doi:10.1371/journal.pone.0031317.g006
Figure 5. Effects of 13-oxo-ODA on rectal temperature in HFD-
fed KK-Ay mice. At 4 weeks of the treatment period, the rectal
temperature of all mice was measured using a thermometer probe.
Data are presented as mean 6 SEM (n= 628). *; p,0.05 versus control.
doi:10.1371/journal.pone.0031317.g005
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compounds that change hepatic lipid metabolism [39–41]. These
beneficial effects of tomato are generally attributed to different
compounds such as carotenoids, vitamins, and flavonoids, but the
actual bioactive compound and molecular mechanisms involved in
the beneficial effects remain unclear. In this study, we revealed 13-
oxo-ODA as a PPARa activator decreasing plasma and hepatic
levels of TG. Given that tomato is the most widely produced crop
worldwide (136 million tons or more a year; FAO statics, 2008)
and that large amounts of tomatoes are preprocessed and
consumed as industrial products worldwide, it is serendipitous
that this bioactive compound is present in processed tomato
products, in particular.
In conclusion, this study indicated that 13-oxo-ODA acts as an
agonist for PPARa not only in vitro but also in vivo where it
activated hepatic PPARa, resulting in suppresses of obesity-
induced plasma and hepatic levels of TG. These findings suggest a
possibility that 13-oxo-ODA is a food-derived functional com-
pound that can regulate hepatic lipid metabolism.
Supporting Information
Figure S1 Effects of 13-oxo-ODA on PPARa target gene
expressions in mouse primary hepatocytes. mRNA
expression levels of CPT1a, AOX, FAT, ACS, and UCP2 in mouse
primary hepatocytes treated with 20 mM CLA or 13-oxo-ODA
and/or 5 mM GW6471 for 24 h. GW6471 is a PPARa´-specific
antagonist. The amounts of mRNAs were quantified by real-time
PCR. The relative amount of each transcript was normalized to
the amount of the 36B4 transcript. The activity of a vehicle control
was set at 100% and the relative expression levels are presented as
fold induction with respect to that in the vehicle control. Data are
presented as mean 6 SEM (n = 4). *; p,0.05, **; p,0.01 versus
control. #; p,0.05 compared between indicated groups.
(TIF)
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